Search

Your search keyword '"Han, Jung Ho"' showing total 644 results
Start Over Author "Han, Jung Ho"
644 results on '"Han, Jung Ho"'

6. Central neurocytoma exhibits radial glial cell signatures with FGFR3 hypomethylation and overexpression

Author

Lee, Yeajina, Chowdhury, Tamrin, Kim, Sojin, Yu, Hyeon Jong, Kim, Kyung-Min, Kang, Ho, Kim, Min-Sung, Kim, Jin Wook, Kim, Yong-Hwy, Ji, So Young, Hwang, Kihwan, Han, Jung Ho, Hwang, Jinha, Yoo, Seong-Keun, Lee, Kyu Sang, Choe, Gheeyoung, Won, Jae-Kyung, Park, Sung-Hye, Lee, Yong Kyu, Shin, Joo Heon, Park, Chul-Kee, Kim, Chae-Yong, and Kim, Jong-Il

Published
2024
Full Text
View/download PDF

15. Current status of advance care planning, palliative care consultation, and end-of-life care in patients with glioblastoma in South Korea.

Author

Suh, Koung Jin, Jung, Eun Hee, Seo, Jeongmin, Ji, So Young, Hwang, Kihwan, Han, Jung Ho, Kim, Chae-Yong, Kim, In Ah, and Kim, Yu Jung

Subjects
GLIOMA treatment, AUTONOMY (Psychology), GLIOMAS, CONVERSATION, CANCER patient medical care, TERTIARY care, LONGITUDINAL method, TERMINAL care, ONCOLOGISTS, PATIENT decision making, ADVANCE directives (Medical care), MEDICAL referrals, PATIENT aftercare, OVERALL survival
Abstract

Background Given the typical trajectory of glioblastoma, many patients lose decision-making capacity over time, which can lead to inadequate advance care planning (ACP) and end-of-life (EOL) care. We aimed to evaluate patients' current ACP and EOL care status. Patients and Methods We conducted a cohort study on 205 patients referred to oncologists at a Korean tertiary hospital between 2017 and 2022. We collected information on sociodemographic factors, cancer treatment, palliative care consultation, ACP, legal documents on life-sustaining treatment (LST) decisions, and aggressiveness of EOL care. Results With a median follow-up time of 18.3 months: 159 patients died; median overall survival: 20.3 months. Of the 159 patients, 11 (6.9%) and 63 (39.6%) had advance directive (AD) and LST plans, respectively, whereas 85 (53.5%) had neither. Among the 63 with LST plans, 10 (15.9%) and 53 (84.1%) completed their forms through self-determination and family determination, respectively. Of the 159 patients who died, 102 (64.2%) received palliative care consultation (median time: 44 days from the first consultation to death) and 78 (49.1%) received aggressive EOL care. Those receiving palliative care consultations were less likely to receive aggressive EOL care (83.3% vs 32.4%, P  < .001), and more likely to use more than 3 days of hospice care at EOL (19.6% vs 68.0%, P  < .001). Conclusions The right to self-determination remains poorly protected among patients with glioblastoma, with nearly 90% not self-completing AD or LST plan. As palliative care consultation is associated with less aggressive EOL care and longer use of hospice care, physicians should promptly introduce patients to ACP conversations and palliative care consultations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial

Author

Kim, Il Han, Park, Chul-Kee, Heo, Dae Seog, Kim, Chae-Yong, Rhee, Chang Hun, Nam, Do-Hyun, Lee, Seung Hoon, Han, Jung Ho, Lee, Se-Hoon, Kim, Tae Min, Kim, Dong-Wan, Kim, Jeong Eun, Paek, Sun Ha, Kim, Dong Gyu, Kim, In Ah, Kim, Yu Jung, Kim, Jee Hyun, Park, Byung-Joo, and Jung, Hee-Won

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Brain Cancer, Clinical Trials and Supportive Activities, Clinical Research, Patient Safety, Brain Disorders, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.5 Radiotherapy and other non-invasive therapies, Adolescent, Adult, Aged, Antineoplastic Agents, Alkylating, Chemotherapy, Adjuvant, Combined Modality Therapy, Dacarbazine, Disease Progression, Female, Follow-Up Studies, Glioblastoma, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Prospective Studies, Temozolomide, Treatment Outcome, Young Adult, Neurosciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

A prospective randomized controlled multicenter phase III trial was conducted to evaluate the effects of neoadjuvant chemotherapy with nimustine (ACNU)-cisplatin (CDDP) when used in conjunction with radiotherapy plus adjuvant temozolomide in patients with newly diagnosed glioblastoma. The study population was randomly assigned into one treatment and one control group. Both groups received radiotherapy followed by six cycles of adjuvant oral temozolomide (150-200 mg/m(2)) for 5 days every 28 days after surgery. Prior to radiotherapy, the treatment group also received two cycles, 6 weeks apart, of neoadjuvant chemotherapy with ACNU (40 mg/m(2)/day) and CDDP (40 mg/m(2)/day) infused continuously for 72 h. The primary end-point was median survival time. The study has closed after interim analysis with a total of 82 patients (48.8% of target number) due to unacceptable high frequency of toxicity profiles in spite of the promising actuarial survival outcome. Median survival time was 28.4 months [90% confidence interval (CI), 21.1 months to not available] in the treatment group and 18.9 months (90% CI, 17.1-27.4 months) in the control group (P = 0.2). The 2-year survival rate and progression-free survival time were 50.9% and 6.6 months (90% CI, 3.5-9.5 months) in the treatment group and 27.8% and 5.1 months (90% CI, 3.8-8.8 months) in the control group. Grade 3 or 4 toxicity was documented in 26 (68.4%) patients in the treatment group, including three neutropenic fever and one death from sepsis, while grade 3 or 4 toxicity occurred in 6 patients (15.8%) in the control group. The high frequency of serious hematological toxicity with ACNU-CDDP neoadjuvant chemotherapy followed by radiotherapy and adjuvant temozolomide limits its usage as primary treatment for glioblastoma. Future studies should aim to identify a subpopulation at reduced risk for ACNU-CDDP toxicity so that the potential of this protocol can be realized.

Published
2011

35. Hearing Outcomes After Stereotactic Radiosurgery for Vestibular Schwannomas : Mechanism of Hearing Loss and How to Preserve Hearing

Author

Han, Jung Ho, Kim, Dong Gyu, Chung, Hyun-Tai, Paek, Sun Ha, Jung, Hee-Won, Schramm, Johannes, Series editor, Akalan, Nejat, Series editor, Benes, Vladimir, Series editor, Di Rocco, Concezio, Series editor, Lobo Antunes, J., Series editor, Pickard, John D., Series editor, Rappaport, Z. Harry, Series editor, and Sindou, Marc, Series editor

Published
2016
Full Text
View/download PDF

39. Cosmosiin Induces Apoptosis in Colorectal Cancer by Inhibiting PD-L1 Expression and Inducing ROS.

Author

Han, Jung Ho, Lee, Eun-Ji, Park, Wonyoung, Choi, Jang-Gi, Ha, Ki-Tae, and Chung, Hwan-Suck

Subjects
PROGRAMMED cell death 1 receptors, COLORECTAL cancer, PROGRAMMED death-ligand 1, IMMUNE checkpoint inhibitors, REACTIVE oxygen species, CANCER cells, APOPTOSIS
Abstract

Immunotherapies, particularly those concerning immune checkpoint inhibitors, have transformed cancer treatment in recent years. Programmed death-ligand 1 (PD-L1) is a key target for immunotherapy that is overexpressed in the cells of colorectal cancer, a widespread malignant cancer that poses a significant healthcare challenge. This study investigated the effects of cosmosiin treatment on colorectal cancer cell lines. Cosmosiin is a naturally occurring flavone glycoside compound that has potential health benefits, including antioxidant and immunomodulatory effects. This study showed that cosmosiin effectively suppresses the expression of PD-L1 and triggers apoptosis, which is facilitated through pathways that are related to reactive oxygen species. These outcomes suggest that cosmosiin could be a promising candidate for an immune checkpoint inhibitor in the treatment of colorectal cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results